By Finance Pulse in Transformative —

Novo Nordisk's CagriSema Shows 23% Weight Loss in Trials

Novo Nordisk's CagriSema demonstrates 23% weight loss in clinical trials, slightly below expectations. Explore its potential impact on weight management solutions.

An aesthetically composed image featuring a sleek laboratory setting, highlighting a vial of CagriSe
Novo Nordisk's CagriSema Shows 23% Weight Loss in Trials

Novo Nordisk's CagriSema showed 23% weight loss in trials, slightly below expectations.

Source